Member Info for Hemo

If I were a betting man, and I must be because I am invested in this fickle piece of s£!t share, I think the 'additional audit work' is around the going concern status of the Company, and the need to raise additional funds to keep the illusion going.

The auditors won't sign off the accounts until they are satisfied the Company can continue to exist for 12 months, and at the moment they are not satisfied.

You’re too negative here. PCR tests still required for those testing positive after an LFT test from a green country as well as visiting amber and red countries. Still demand for PCR tests.

Looking for a German speaking accounts payable role so we must be doing a bit of business over there? It hasn’t really featured in our newsflow though?

I’ve read Scott Sargent’s LinkedIn profile and the companies he has worked for are very impressive, Roche, Illumina, Qiagen.

He worked a long time at Roche but his last three roles have been less than 3 years so it’s not clear how long he will stay. Who cares though if he delivers and the company will probably be sold in that timeframe anyway?! I’m sure he’ll be given some nice options.

The 6% growth at Qiagen is underwhelming but he wasn’t there a full year and who knows the obstacles he faced? There are more impressive sales growth figures on his CV so surprised they didn’t mention those.

I would be interested to know why he left Qiagen after only 2 years though and why he was allowed to join YGEN immediately. That sounds a little iffy.

Anyway I wish him all the best, the opportunity is immense and if he succeeds then we all succeed.

MAG currently uses an outfit called Collinson at the moment for their COVID-19 testing.

Does anyone know if Collinson use our PCR product?

I wonder why MAG is re-tendering - not happy with Collinson?

I assume this isn’t the specific COVID testing contract expected by Brokerman Dan?

I thought Lyn's presentation last week was broadly helpful, humble, timely and reassuring. The market has reacted well and the predatory trading seems to have stopped for now.

My only concern, and I have asked this of Walbrook, is if the previous 2020/21 revenue forecast was £25m and it seems we have lost £5.5m of revenue (deferred) as described by Lyn what could make 2020/21 revenue fall further from £19.5m (£25m less £5.5m) to the bottom of the new range given i.e. £18m? What other expected revenue is at risk given there are only six weeks left of the current financial year? To my mind 2020/21 revenue should be at least £19.5m and anything less than that will disappoint the market.

Walbrook's response was there was nothing further to add to the presentation and full year revenues are expected to be in the range of £18-20m.

I’ve been waiting over 10 years so I can wait a little longer!

Why haven't they got any news to announce ffs?!!

So much promised in the last update nearly 7 weeks ago.

So we are now trading at less than four times expected FY21 sales and just over three times FY22 sales.

Previously we were told our type of company is valued in the region of 5-10 times next years sales, which would mean a potential uplift of either 50% or a tripling of the current share price, or somewhere between 20p to 40p.

We are an absolute steal unless of course you don't believe the revenue forecasts.

Having just watched the investor video again from December 2020 I can't fathom what could be going wrong because there was so much they were confident in delivering and the revenue forecasts were basically reiterated this month.

Something just isn't right. I would definitely take 25p though to end this misery. We have to be worth that.

What is the newsflow that has come out of Coastal Genomics since we acquired it?

We were promised news of blue chip clients but nothing as of yet.

I don’t think this is going very well given the silence.

The lack of news on this, COVID, Iona NX roll out, US reproductive contracts is most frustrating and is reflected in the share price.

It’s complete bull$hit that postings on this BB will put off new investors. Stop using that as an excuse, it’s ridiculous. You’re a bunch of Neville Chamberlains.

What is putting investors off is poor communication and lack of delivery from the Company.

Simple.

This BB has deteriorated significantly however in the recent past, however. It’s quality resembles the rubbish performance of the Company.

The big question for me are we able to keep our AIM listing beyond 28 January 2021?

This is not answered in the RNS and remains our biggest risk apart from completing the transaction and having enough funds to keep going until March 2021.

I would like to know your source but I agree that we are very vulnerable to a takeover right now and at a price that is lower than most of us want or expected only 12 months ago.

This would be the consequence of the poor performance and communication over the last 12 months.

If we agree a deal with the RTO candidate we are at the mercy of the AIM authorities because the RTO has to happen by 28 January to preserve our listing. That is impossible because the deal will need to be approved by shareholders etc and that will not happen by 28 January so the AIM authorities will have to show flexibility. Does anyone know if this has happened elsewhere?It’s not a great place to be in leaving it so close to the wire but hardly surprising given the known incompetence of the Board.

All I want right now is an update on the core, core business ie NIPT.

We are not hearing enough regularly about that in terms of new contracts, NX rollout etc.

I would have expected more by now and the ongoing lockdown suggests this part of the business is still under significant pressure.

We all know that lockdowns damage the core business as well so what is happening in the world is unlikely to improve NIPT sales.

I do not believe we will hit £25m sales in FY21, particularly as COVID-19 testing has not taken up enough of the slack.

But I believe in the company in the medium to long term.

We must be very vulnerable to a takeover right now and that is one of the risks of failing both to communicate properly and to deliver on expectations, leading the share price to languish.

Healthcare M&A is very strong at the moment and is expected to continue that way into 2021. I wouldn't be surprised if someone takes us out soon and then our misery will be over.

Totally agree with all the comments about poor communication and I think it has deteriorated.

One example, last year the company gave us notice of the half year results on 12 November but we have had nothing this year so far and it is one week later.

What is holding the Board back from improving communication and giving more news? Can’t be share options or the employee incentive plan any more surely? Recruiting 20 odd staff is noteworthy so there must be something to shout about but I can’t work out why they wouldn’t want a higher price to reflect progress, improve sentiment, reduce the price paid for acquisitions etc.

I think given the poor H1 revenue numbers we should be bracing ourselves for a loss of at least £1-2m when results are announced in December.

The full year revenue forecast has been maintained at £25m so we need guidance on that number to be reiterated.

If that number is achieved I’m sure we will see a profit for the full year but expectations need to be managed for the half year.